Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma

Current Opinion in Oncology

Volumn 23, Issue 4, 2011, Pages 373-378

  Crago, Aimee M ^a   Singer, Samuel ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

CDK4; liposarcoma; MDM2; well differentiated dedifferentiated

Indexed keywords

CYCLIN DEPENDENT KINASE 4; PROTEIN MDM2;

CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CLINICAL EXAMINATION; HUMAN; LIPOSARCOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; TISSUE MICROARRAY;

CELL DEDIFFERENTIATION; CELL DIFFERENTIATION; CHROMOSOMES, HUMAN, PAIR 12; COMBINED MODALITY THERAPY; CYCLIN-DEPENDENT KINASE 4; HUMANS; LIPOSARCOMA; NEOPLASM RECURRENCE, LOCAL; PROTO-ONCOGENE PROTEINS C-MDM2;

EID: 79958857301     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32834796e6     Document Type: Review

References (25)

1. Singer S, Antonescu CR, Riedel E, Brennan MF. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg 2003; 238:358-370; discussion 370-351.
2. Dalal KM, Kattan MW, Antonescu CR, et al. Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg 2006; 244:381-391.
3. Fletcher CD, Akerman M, Dal Cin P, et al. Correlation between clinicopathological features and karyotype in lipomatous tumors. A report of 178 cases from the Chromosomes and Morphology (CHAMP) Collaborative Study Group. Am J Pathol 1996; 148:623-630. (Pubitemid 26056746)
4. Meis-Kindblom JM, Sjogren H, Kindblom LG, et al. Cytogenetic and molecular genetic analyses of liposarcoma and its soft tissue simulators: recognition of new variants and differential diagnosis. Virchows Arch 2001; 439:141-151. (Pubitemid 32758907)
5. Murphey MD, Arcara LK, Fanburg-Smith J. From the archives of the AFIP: imaging of musculoskeletal liposarcoma with radiologic-pathologic correlation. Radiographics 2005; 25:1371-1395. (Pubitemid 41695351)
6. Rosai J, Akerman M, Dal Cin P, et al. Combined morphologic and karyotypic study of 59 atypical lipomatous tumors. Evaluation of their relationship and differential diagnosis with other adipose tissue tumors (a report of the CHAMP Study Group). Am J Surg Pathol 1996; 20:1182-1189. (Pubitemid 26336841)
7. Weiss SW. Lipomatous tumors. Monogr Pathol 1996; 38:207-239.
8. McCormick D, Mentzel T, Beham A, Fletcher CD. Dedifferentiated liposarcoma. Clinicopathologic analysis of 32 cases suggesting a better prognostic subgroup among pleomorphic sarcomas. Am J Surg Pathol 1994; 18:1213-1223. (Pubitemid 24362434)
9. Fletcher CD. Pleomorphic malignant fibrous histiocytoma: fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma. Am J Surg Pathol 1992; 16:213-228.
10. Binh MB, Sastre-Garau X, Guillou L, et al.MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. Am J Surg Pathol 2005; 29:1340-1347. (Pubitemid 41368770)
11. Rosenberg SA, Tepper J, Glatstein E, et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limbsparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 1982; 196:305-315. (Pubitemid 12052461)
12. Bonvalot S, Miceli R, Berselli M, et al. Aggressive surgery in retroperitoneal soft tissue sarcoma carried out at high-volume centers is safe and is associated with improved local control. Ann Surg Oncol 2010; 17:1507-1514.
13. Lewis JJ, Leung D, Woodruff JM, Brennan MF. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg 1998; 228:355-365. (Pubitemid 30191698)
14. Park JO, Qin LX, Prete FP, et al. Predicting outcome by growth rate of locally recurrent retroperitoneal liposarcoma: the one centimeter per month rule. Ann Surg 2009; 250:977-982.
15. Eilber FC, Eilber FR, Eckardt J, et al. The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. Ann Surg 2004; 240:686-695; discussion 695-687.
16. Pawlik TM, Pisters PW, Mikula L, et al. Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate-or high-grade retroperitoneal soft tissue sarcoma. Ann Surg Oncol 2006; 13:508-517.
17. Barretina J, Taylor BS, Banerji S, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet 2010; 42:715-721.
18. National Institutes of Health. ClinicalTrials.gov. http://www. clinicaltrials.gov. [Accessed 10 February 2011].
19. Oliner JD, Pietenpol JA, Thiagalingam S, et al. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993; 362:857-860. (Pubitemid 23132165)
20. Oliner JD, Kinzler KW, Meltzer PS, et al. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992; 358:80-83.
21. Fang S, Jensen JP, Ludwig RL, et al. Mdm2is a RINGfinger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 2000; 275:8945-8951. (Pubitemid 30180252)
22. Vu BT, Vassilev L. Small-molecule inhibitors of the p53-MDM2 interaction. Curr Top Microbiol Immunol 2011; 348:151-172.
23. Singer S, Socci ND, Ambrosini G, et al. Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well differentiated and dedifferentiated liposarcoma. Cancer Res 2007; 67:6626-6636. (Pubitemid 47105508)
24. Italiano A, Bianchini L, Gjernes E, et al. Clinical and biological significance of CDK4 amplification in well differentiated and dedifferentiated liposarcomas. Clin Cancer Res 2009; 15:5696-5703.
25. Peng T, Zhang P, Liu J, et al. An experimental model for the study of well differentiated and dedifferentiated liposarcoma: deregulation of targetable tyrosine kinase receptors. Lab Invest 2010. doi: 10.1038/labinvest.2010.1185.